Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

The interplay of lung cancer, COVID-19, and vaccines (CROSBI ID 317533)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Trivanović, Dragan ; Peršurić, Željka ; Agaj, Andrea ; Jakopović, Marko ; Samaržija, Miroslav ; Bitar, Lela ; Pavelić, Krešimir The interplay of lung cancer, COVID-19, and vaccines // International journal of molecular sciences, 23 (2022), 23; 15067, 15. doi: 10.3390/ijms232315067

Podaci o odgovornosti

Trivanović, Dragan ; Peršurić, Željka ; Agaj, Andrea ; Jakopović, Marko ; Samaržija, Miroslav ; Bitar, Lela ; Pavelić, Krešimir

engleski

The interplay of lung cancer, COVID-19, and vaccines

Patients with cancer are more susceptible to a higher risk of coronavirus infection and its severe complications than the general population. In addition, these patients were not included in the pivotal clinical trials for COVID-19 vaccines. Therefore, considerable uncertainty remains regarding the management of cancer patients during the COVID-19 pandemic and the safety of COVID-19 vaccinations in cancer patients. In this review, we summarize the current knowledge generated from the beginning of the COVID-19 pandemic on the vulnerability of cancer patients to the coronavirus disease, as well as the effectiveness of COVID-19 vaccines in this population. We also discuss the available data on the effects of anticancer treatment with immune checkpoint inhibitors on the immune responses to SARS-CoV-2 in cancer patients. Special attention in this review will be given to patients with lung cancer, as such patients are at an increased risk for severe effects from COVID-19.

COVID-19 ; vaccine ; solid cancers ; lung cancer ; immune checkpoint inhibitors

Patients with cancer are more susceptible to a higher risk of coronavirus infection and its severe complications than the general population. In addition, these patients were not included in the pivotal clinical trials for COVID-19 vaccines. Therefore, considerable uncertainty remains regarding the management of cancer patients during the COVID-19 pandemic and the safety of COVID-19 vaccinations in cancer patients. In this review, we summarize the current knowledge generated from the beginning of the COVID-19 pandemic on the vulnerability of cancer patients to the coronavirus disease, as well as the effectiveness of COVID-19 vaccines in this population. We also discuss the available data on the effects of anticancer treatment with immune checkpoint inhibitors on the immune responses to SARS-CoV-2 in cancer patients. Special attention in this review will be given to patients with lung cancer, as such patients are at an increased risk for severe effects from COVID-19.

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

23 (23)

2022.

15067

15

objavljeno

1422-0067

10.3390/ijms232315067

Povezanost rada

nije evidentirano

Poveznice
Indeksiranost